Caribou Biosciences Files 8-K on Shareholder Vote & Financials
Ticker: CRBU · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1619856
| Field | Detail |
|---|---|
| Company | Caribou Biosciences, INC. (CRBU) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, regulatory-filing
Related Tickers: CRBU
TL;DR
CRBU filed an 8-K for shareholder votes and financials. Keep an eye on governance updates.
AI Summary
On June 13, 2024, Caribou Biosciences, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements. The company, incorporated in Delaware, is involved in biological products and is headquartered in Berkeley, California.
Why It Matters
This filing indicates important corporate actions and financial reporting, which are crucial for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine regulatory filing for corporate actions and financial reporting, not indicating immediate operational or financial distress.
Key Numbers
- 001-40631 — SEC File Number (Identifies the company's filing with the SEC)
- 45-3728228 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Caribou Biosciences, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Berkeley, California (location) — Principal Executive Offices
- June 13, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What is the primary business of Caribou Biosciences, Inc.?
Caribou Biosciences, Inc. is involved in Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 13, 2024.
Where are Caribou Biosciences, Inc.'s principal executive offices located?
Caribou Biosciences, Inc.'s principal executive offices are located at 2929 7th Street, Suite 105, Berkeley, California 94710.
What is the SEC Act under which this report is filed?
This report is filed under the 1934 Act.
Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-06-14 16:03:27
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CRBU NASDAQ Global
Filing Documents
- crbu-20240613.htm (8-K) — 34KB
- 0001619856-24-000050.txt ( ) — 162KB
- crbu-20240613.xsd (EX-101.SCH) — 2KB
- crbu-20240613_lab.xml (EX-101.LAB) — 23KB
- crbu-20240613_pre.xml (EX-101.PRE) — 13KB
- crbu-20240613_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024, Caribou Biosciences, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. A more detailed description of each proposal is set forth in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 25, 2024. Proposal 1 - Election of Three Class III Directors Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2027 annual meeting of stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation, or removal. Nominee Votes For Votes Withheld Broker Non-Votes Rachel Haurwitz, Ph.D. 57,375,324 2,287,189 13,621,407 Dara Richardson-Heron, M.D. 50,232,080 9,430,433 13,621,407 Natalie Sacks, M.D 50,173,915 9,488,598 13,621,407 Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, by the following votes: Votes For Votes Against Votes Abstain 73,021,434 231,293 31,193
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Caribou Biosciences, Inc. Date: June 14, 2024 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer